Bone densitometry vendor Lunar last month announced that its third-quarter revenues would likely decline compared with the same quarter last year. Lunar of Madison, WI, pointed to below-average sales of densitometers in the U.S. and Asia as a reason for
Bone densitometry vendor Lunar last month announced that its third-quarter revenues would likely decline compared with the same quarter last year. Lunar of Madison, WI, pointed to below-average sales of densitometers in the U.S. and Asia as a reason for the anticipated down quarter (end-March 31).
While the company attributed the dip in Asian sales to the region's recent currency difficulties, U.S. demand has been shifting away from traditional hospital markets toward lower priced systems for physician offices. In an effort to improve access to these emerging markets, Lunar is implementing new distribution channels. The company expects to soon announce new national distributor relationships for its existing physician-office products, as well as its Achilles ultrasound densitometer, which is pending Food and Drug Administration premarket approval.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.